CCXI / ChemoCentryx's stock jumps 80% after receiving FDA approval for vasculitis drug

Shares of ChemoCentryx, Inc. (NASDAQ: CCXI) are skyrocketing Thursday following a groundbreaking announcement for the biopharmaceutical company. Why I more_horizontal

Amgen (AMGN) is buying ChemoCentryx (CCXI) for $4 billion in cash. These are the details. more_horizontal

In the wake of its first quarter earnings report, ChemoCentryx ran as much as 25% on Friday as the broader market fell. The move could mark an importa more_horizontal

ChemoCentryx (CCXI) posts a wider-than-anticipated Q1 loss and a revenue lag. However, product sales of CCXI's recently approved drug Tavneos grow fiv more_horizontal

ChemoCentryx Inc (NASDAQ: CCXI) shares are trading higher by 21.45% at $19.00 after the company reported first-quarter results. ChemoCentryx reported more_horizontal

ChemoCentryx, Inc. (NASDAQ:CCXI ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Dr. Thomas Schall – Chairman, Preside more_horizontal

ChemoCentryx (CCXI) delivered earnings and revenue surprises of -83.33% and 78.77%, respectively, for the quarter ended March 2022. Do the numbers hol more_horizontal

ChemoCentryx (CCXI) posts a wider year-over-year loss in the fourth quarter and sales miss estimates. Lead drug Tavneos has been launched in the Unite more_horizontal